Cannabis News

Psilocybin could be the key to unlocking key treatments for mental health issues. "Existing antidepressant drugs don't work well for an estimated 30 to 50 percent of the people who try them; when they do work, the effects can take weeks to kick in. Psilocybin, a compound that can profoundly alter consciousness and perceptions of reality, might be a powerful alternative, says Roland Griffiths, a neuropsychopharmacologist at Johns Hopkins School of Medicine," as quoted by Science News.

Better still, the drug can reportedly promote neuroplasticity in the brains of rats. According to a study in the Journal of Psychopharmacology, "The present study demonstrates that psilocybin rapidly induces gene expression related to neuroplasticity, biased towards the prefrontal cortex, compared to the hippocampus. Findings provide further evidence for the rapid plasticity-promoting effects of psilocybin."

The U.S. is seeing broader support of psilocybin use, as well.

For example, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, "An estimated 1 in every 5 adults in Oregon is coping with a mental health condition," 20 doctors and other health care workers wrote in the voters' pamphlet.

"We support Measure 109 because it provides a new treatment for many that might break through where others fall short."

Better Plant Sciences (CSE: PLNT) (OTCQB: VEGGF) Just Received Health Canada Approval to Advance its Psilocybin Research

The company just announced that its majority owned subsidiary NeonMind Biosciences obtained Health Canada approval to advance its preclinical trial on psilocybin-based research. The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial.

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

For more information, visit the company's website at https://betterplantsciences.com.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.

Contact Information:
2818047972
ty@lifewatermedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68472

News Provided by Newsfile via QuoteMedia

Canopy Growth Announces Industry Veteran Christelle Gedeon As New Chief Legal Officer

Gedeon's demonstrated cannabis and commercial expertise will further Canopy Growth's Strategy for North American Cannabis Leadership

Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, is pleased to announce that the appointment of Christelle Gedeon Ph.D., as the Company's new Chief Legal Officer.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open its First Branded Dispensary in Arizona

Grand opening on August 2 in downtown Phoenix's Roosevelt Row neighborhood

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its first Trulieve-branded dispensary in Arizona . Located at 1007 N. 7th St., the doors open at 8 a.m. on Tuesday, August 2 with ongoing hours of 8 a.m. 10 p.m. seven days a week. This is the first cannabis dispensary in the Roosevelt Row neighborhood in downtown Phoenix .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Second Quarter 2022 Results Conference Call on August 10, 2022

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Wednesday, August 10, 2022 at 8:30 AM Eastern Time following the release of its second quarter 2022 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers , Chief Financial Officer Alex D'Amico, and President Steve White will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

North American toll free: 1-888-317-6003

passcode: 6100603

International: 1-412-317-6061

passcode: 6100603

A live audio webcast of the conference call will be available at:
https://app.webinar.net/eNPDleGz6oj

An archived replay of the webcast will be available at:
https://trulieve.gcs-web.com/events-presentations

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
Twitter: @Trulieve

Investor Contact

Christine Hersey , Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact

Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-second-quarter-2022-results-conference-call-on-august-10-2022-301597504.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/02/c6113.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings Launches Cannabis-Infused Gummies in Minnesota

The addition of edibles to Minnesota's medical cannabis program allows for greater choices for certified cannabis patients

- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS) (OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced the addition of cannabis-infused gummies to its Vireo brand in Minnesota in accordance with Minnesota's new regulations effective Aug. 1 allowing certified medical cannabis patients in the state to purchase certain edible products containing cannabis.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Cresco Labs to Hold Second Quarter 2022 Earnings Conference Call on August 17, 2022

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco Labs" or "the Company"), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced that it will report financial results for the second quarter ended June 30 th , 2022, on Wednesday, August 17th, 2022, before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cannabis Weekly Round-Up: Tilray Jumps Thanks to Latest Fiscal Results

Cannabis Weekly Round-Up: Tilray Jumps Thanks to Latest Fiscal Results

Shares of Tilray Brands (NASDAQ:TLRY,TSX:TLRY) jumped this week after the company released results for its fourth fiscal quarter and full 2022 year.

Also this past week, a Canadian cannabis producer announced a share consolidation plan.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Latest Press Releases

Related News

×